Introduction
Oesophagus cancer, cardia cancer and gastric cancer are three of the most commonly seen malignant tumor of gastrointestinal cancer. Oesophagus cancer is start in the inner layer and grows outward. Since two types of cell can line the oesophagus; there are two main types of oesophagus cancer.
1. Squamous cells carcinoma 2. Adenocarcinomas Squamous cell carcinoma is normally linked with squamous cells. Cancer starting in these cells is called squamous cell carcinoma. This type of cancer can occur anywhere along the oesophagus.
Once, squamous cell carcinoma was by far the most common type of oesophagus cancer in worldwide. The use of tobacco products, including cigarettes, cigars, pipes, and chewing tobacco is a major risk factors for esophagus cancer. The more a person uses tobacco and longer it is used, the higher the cancer risk. Someone who smokes a pack of cigarettes a day or more has atleast twice the chance of getting adenocarcinoma of the oesophagus than a non smoker. The link to squamous cell carcinoma of oesophagus is even stronger. The risk of oesophagus cancer goes down if tobacco use stop. Drinking alcohol also increases the risk of oesophagus cancer. The chance of getting oesophagus cancer goes up with more consumption of alcohol. Combining smoking and alcohol consumption raise the risk of oesophagus cancer much more than using either alone (1) . Some dilatory factors that have been closely associated with oesophagus cancer are betel nut chewing, hot food and beverages. The incidence rate of oesophagus cancer is 7.6 per 100000 in men and 5.7 per 100000 in women in 2006 but recently 8.63 per 100000 in men and 4.39 per 100000 in women (2, 3, 4) . Oesophagus cancer including squamous cell carcinoma and adenocarcinoma considered as serious malignancy with respect to prognosis and a fetal outcome in the great majority of cases (5, 6) . Oesophagus carcinoma affects more than 450000 people worldwide and the incidence rapidly increasing (7) . Currently, oesophagus cancer is the eights most common incident cancer in the world because of its extremely aggressive nature and poor survival rate (8, 9) . Incidence of oesophagus cancer has increased sharply over the past few decades, both by period and birth cohort. Etiological studies are required to explain the rapid increase of this lethal cancer (10) . This oesophagus cancer is 3 to 4 times more common among men than among women (1). (11) . CEA currently classified under the immunoglobulin super family and functions as an intracellular adhesion molecule. In the recent years CEA has been widely used as a tumor marker in the diagnosis and monitoring of some malignancies (12) . Since the 1990s tumor marker including CEA and other have been widely used to monitor oesophagus cancer progression and even to assess the prognosis of oesophagus cancer patients although their specificities have not been satisfactory (13, 14, 15) . Therefore, the serum CEA level may be a pertinent index of tumor progression for patients with oesophagus cancer.
In trial of chemotherapy for patients with an oesophagus cancer and who had undergone a noncurative resection, we determined serum CEA levels before and after different cycles of cisplastin based chemotherapy in oesophagus cancer patients. Measurement of CEA in esophageal cancer patients poses a continuing challenge to surgeon. Major predicators of survival are the stage of the tumor at the time of presentation and the extent of the surgical restriction performed [16] . Little emphasis has been given to the value of detection of recurrent disease which has been reliant a crude method such as development of dysphasia or systemic metastases both of which herald the patients" rapid decline. The tumor marker CEA is often elevated in patients with tumor of the gastrointestinal tract [17] . Elevated CEA levels have been used as a marker for recurrent colorectal cancer and prognostic marker for second surgery [18] . CEA has been reported to be beneficial in determining the relapse and the follow up of the response to the chemotherapy or treatment of the patients with gastric and esophageal cancer [19] . , we determined serum CEA levels before and after different cycles of cisplastin based chemotherapy in oesophagus cancer patients. All Values are expressed in IU/L, "P" Value <0.001. Table 2 mean CEA activity (mean±SD) in control using commercial kits from accu-bind on ELISA micro plate Immunoenzymometric assay was 1.55±0.30. Serum CEA activity of oesophagus cancer patients was 7.33 ± 1.12. CEA level was significantly higher in oesophagus cancer patients than control (p<0.001). Table 3 shown that mean CEA level (mean±SD) in control using commercial kits from accu-bind on ELISA micro plate Immunoenzymometric assay was 1.55±0.30. CEA level in oesophagus cancer patients before chemotherapy (Stage I) was 17.33 ± 1.12. CEA level was significantly higher in oesophagus cancer patients than control (p<0.001). After first, Second and third cycle of chemotherapy CEA level was 8.01± 2.64, 2.56±0.23, and 1.44±0.43 respectively. CEA level was significantly decreased after different cycles of chemotherapy than before chemotherapy (<0.001). After first and second cycle of chemotherapy CEA level was significantly increased than control group but after third cycle of chemotherapy CEA level was normal. 
RESULTS

As shown in
DISCUSSION
Knowledge of diagnostic and prognostic factors are essential for the management of individual patients and these factors should be taken into account in the design of randomised trials and in interpreting the result of such trials. Serum tumor markers have been used in aiding the diagnosis of gastrointestinal cancers for a long time. Previous studies reported that the elevated serum values reflect the increased secretion of tumor antigens by tumor itself [21] . However mild elevation of serum tumor marker level in a number of early-stage of cancer has been always difficult to justify as many benign pathologies may frequent because such changes. The clinical use of tumor markers is much more beneficial in determination of prognosis assessing response to treatment and detection of early recurrence [22, 23] .
Carcinoembryonic antigen (CEA) is used predicting & in monitoring patients with advanced cancer. Tumor markers alone cannot be used to asses response, but could be used to confirm complete response -serum tumor markers have been used in aiding the diagnosis of gastrointestinal cancers for a long time. Previous studies reported that the elevated serum values reflect the increased secretion of tumor antigen of tumor itself. However mild elevation of serum tumor markers level in a number of early stage cancers has always been difficult to justify as many benign pathologies may frequently cause such changes. The clinical use of tumor markers is much more beneficial in determination of prognosis is assessing response to treatment & detection of early recurrences [24] .
In the study various tumor markers such as CEA has been investigated in the serum of gastric adenocarcinomas to markers. Llyas Tuncer show the serum CEA level was found to be higher in 70% cases in both cases [25] . CEA is one of the most reliable tumor associated markers used for [26] , reported that CEA was positive in 27% of the patients with oespohagas cancer. In the same study it has been reported that the positivity rate of CEA was correlated with the stage of the disease.
In our study the activity of total CEA in stage I before chemotherapy was significantly higher than control (before esophagus cancer) but after first, second and third cycle of chemotherapy activity of total CEA was significantly decreased.
CONCLUSION
Based on the data from our study, it can be stated that serum CEA measurement in plasma may be useful tumor marker in esophageal cancer, its activity might helpful to predict the response of chemotherapy in advance stage of cancer. An initial increased level of CEA before and first cycle of chemotherapy may not indicate tumor progression, but may be represent a transient tumor marker surge phenomenon after second and third cycle of chemotherapy in patients responding to treatment.. Statistically significant change in tumor marker CEA level during the process of treatment in esophageal cancer patients, with a positive response and no established disease progression during study period, near about 12 months after the treatment, point to CEA as an important predictive factor.
